Wellspect HealthCare Announces U.S. Medicare Reimbursement Access for Surity™ Urinary Management Portfolio

Wellspect's Surity catheters gain Medicare coding, but financial impact remains unproven.

What the company is saying

Wellspect HealthCare, a subsidiary of Dentsply Sirona (NASDAQ: XRAY), is announcing that its Surity portfolio—including the Surity Urinary Management System and Surity Female and Male External Catheters—may now be covered by traditional Medicare for eligible patients when medically necessary. The company frames this as a major milestone for access and support for people with severe urinary incontinence, emphasizing the product's non-invasive nature and features like gentle suction, quiet operation, and odor management. Coding verification has been secured under HCPCS codes A6590 and E2001, which the company claims will support reimbursement for eligible beneficiaries. Chris Schlenk, Group Vice President at Wellspect HealthCare, is quoted to underscore the importance of this step for patients and caregivers. The announcement highlights the scale of the problem—over 13 million people in the U.S. live with urinary incontinence—and positions Surity as a new choice in the market. The company also notes that Surity has become one of the most searched external catheter brands on Google, but does not provide supporting data.

What the data suggests

The announcement confirms that the Surity Female and Male External Catheters have received coding verification under HCPCS code A6590, and the Surity Urinary Management System under code E2001, enabling potential Medicare reimbursement for eligible users. The Surity Urinary Management System launched in the United States on August 18, 2026, completing the portfolio, with the external catheters introduced earlier in 2026. Wellspect employs approximately 1,200 people worldwide and operates in over 40 countries. The company cites more than 13 million people in the U.S. affected by urinary incontinence, indicating a large addressable market. However, there are no disclosed figures for actual Medicare reimbursement approvals, sales, or patient uptake. Claims about being a leading Google search brand and product benefits are not substantiated by data or user feedback. The announcement is operationally specific but lacks financial or clinical evidence to quantify the impact of the Medicare milestone.

Analysis

The announcement is generally positive in tone, highlighting the coding verification for Medicare reimbursement and the recent launch of the Surity™ portfolio in the United States. The key realised facts are the product launches and coding verification, which support potential reimbursement access but do not guarantee actual Medicare coverage or uptake. Several claims, such as the significance of the Medicare milestone and the product's comfort, discretion, and reliability, are not substantiated with clinical, financial, or user data. The statement that Surity has become one of the most searched brands on Google is promotional and unsupported by comparative metrics. No financial results, sales figures, or profitability metrics are disclosed, limiting the ability to assess the true impact of these developments. The gap between narrative and evidence is moderate: while operational progress is clear, the announcement inflates the significance of the milestone and product features without measurable outcomes.

Risk flags

• ●The announcement does not disclose any sales, reimbursement approvals, or patient uptake figures, so the financial impact of Medicare coding remains speculative. Without evidence of actual adoption, the commercial benefit is uncertain.
• ●Claims regarding product comfort, discretion, and reliability, as well as being a top-searched brand, are not supported by clinical data, user feedback, or comparative metrics. This reliance on promotional language introduces execution risk if the market response does not match expectations.
• ●Medicare reimbursement is subject to individual payer decisions and eligibility criteria, which may limit the actual number of beneficiaries who can access the products. The company explicitly states that coverage is not guaranteed and may vary.

Bottom line

Wellspect HealthCare has achieved Medicare coding verification for its Surity urinary management products, potentially expanding access for eligible U.S. patients and targeting a market of over 13 million people. While this operational milestone is necessary for reimbursement, the company has not disclosed any data on actual reimbursement approvals, sales, or patient adoption, leaving the financial impact unproven. The announcement relies heavily on promotional claims about product benefits and market interest without supporting evidence. Investors should recognize that while coding is a prerequisite for growth, revenue and profit gains will depend on real-world uptake and payer decisions. The most important takeaway is that this is a foundational step, but measurable financial results are still needed to validate the commercial opportunity.

Announcement summary

(NASDAQ: XRAY) Wellspect HealthCare announced that its Surity™ portfolio, which includes the Surity™ Urinary Management System and Surity™ Female and Male External Catheters, may be covered by traditional Medicare for eligible beneficiaries when medically necessary. The Surity™ Female and Male External Catheters have received coding verification under Healthcare Common Procedure Coding System (HCPCS) code A6590, and the Surity™ Urinary Management System under code E2001, supporting reimbursement access for beneficiaries who meet applicable coverage criteria. Chris Schlenk, Group Vice President at Wellspect HealthCare, stated that Medicare reimbursement for the Surity™ portfolio is a significant milestone in supporting individuals with permanent urinary incontinence. The Surity™ portfolio is designed to provide non-invasive, comfortable, discreet, and reliable urine management solutions, featuring gentle suction technology, intuitive design, quiet operation, and odor management to assist in overnight care. There are more than 13 million people living with urinary incontinence in the United States. The Surity™ Female and Male External Catheters were introduced earlier in 2026, and the Surity™ Urinary Management System was launched in the United States on August 18, 2026, completing the full Surity portfolio. Since its introduction, Surity has become one of the most searched external catheter brands on Google. Wellspect HealthCare is a subsidiary of Dentsply Sirona (NASDAQ: XRAY) and employs approximately 1,200 people worldwide. Wellspect is headquartered in Mölndal, Sweden, and operates in more than 40 countries. Dentsply Sirona is listed on Nasdaq under the symbol XRAY.

Disagree with this article?